

The IMASH Trial

Intravenous Magnesium sulfate in Aneurysmal Subarachnoid Hemorrhage

Commenced: August 2006.

Aim: The IMASH trial is a randomised, placebo-controlled, double-blinded, multi-centre trial to evaluate the effect that intravenous magnesium sulfate infusion has on the clinical outcome of patients with ASAH.

Primary Endpoint : Extended Glasgow Coma Scale at six months

Secondary Endpoint: Incidence of clinical vasospasm, Barthel index; modified Rankin score, modified national health stroke score, MCA velocities, other major complications

Eligibility: This will be a large, randomized, parallel-group, controlled trial, with patients randomly allocated to either MgSO₄ or saline infusion. Ethics Committee approval and informed consent will be obtained at all study centres

Inclusion Criteria:

1. ASAH (as indicated by CT scan or lumbar puncture and an intracranial aneurysm confirmed by computer tomographic or conventional angiography)
2. Within 48 hours of ictus (hemorrhage event)

Exclusion Criteria:

3. Pregnancy
4. Major renal, hepatic or pulmonary disease
5. Major cardiac disease or recent myocardial infarct (< 6 months)
6. Age less than 18 years
7. Moribund condition on admission (defined as a patient that is in such a poor clinical condition that further active neurosurgical management would not be anticipated)